

**FORWARDHEALTH**  
**PRIOR AUTHORIZATION / BRAND MEDICALLY NECESSARY ATTACHMENT (PA/BMNA)**

**Instructions:** Type or print clearly. Before completing this form, read the Prior Authorization/Brand Medically Necessary Attachment (PA/BMNA) Completion Instructions, F-11083A. Providers may refer to the Forms page of the ForwardHealth Portal at [www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage](http://www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage) for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Brand Medically Necessary Attachment (PA/BMNA) form signed by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at (800) 947-9627 with questions.

---

**SECTION I — MEMBER INFORMATION**

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number

3. Date of Birth — Member

---

**SECTION II — PRESCRIPTION INFORMATION**

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Directions for Use

8. Name — Prescriber

9. National Provider Identifier — Prescriber

10. Address — Prescriber (Street, City, State, ZIP+4 Code)

11. Telephone Number — Prescriber

---

**SECTION III — CLINICAL INFORMATION**

12. Diagnosis — Primary Code and / or Description

As required in DHS 107.10(3)(c), Wis. Admin. Code, when a prescription is for a BMN drug, the prescriber is required to write "brand medically necessary" in his or her own handwriting. This required statement may be handwritten either directly on the prescription or on a separate order attached to the original prescription. Typed certification, signature stamps, or certification handwritten by someone other than the prescriber does not satisfy this requirement. Blanket authorization for an individual member, drug, or prescriber is not acceptable documentation.

13. Is "brand medically necessary" handwritten by the prescriber on the prescription or on a separate order attached to the original prescription?

Yes  No

14. Is the brand medically necessary request for one of the following drugs?

Yes  No

- Anticonvulsant used to treat a seizure disorder.
- Cellcept.
- Coumadin.
- Neoral.
- Prograf.

If yes, skip Elements 15-17 and proceed to Elements 18-19.

*Continued*



DT-PA008-008

---

**SECTION III — CLINICAL INFORMATION (Continued)**

---

15. Has the member experienced an unsatisfactory therapeutic response or clinically significant adverse drug reaction with at least two different manufacturers of the generic equivalent drug?  Yes  No

If yes, list the manufacturer or National Drug Code (NDC), dates taken, and indicate the specific details about the unsatisfactory therapeutic response(s) or clinically significant adverse drug reaction(s) that can be directly attributed to the generic equivalent drugs.

Manufacturer / NDC \_\_\_\_\_ Dates Taken \_\_\_\_\_

Indicate in the space provided the specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction that can be directly attributed to this generic drug.

\_\_\_\_\_

Manufacturer / NDC \_\_\_\_\_ Dates Taken \_\_\_\_\_

Indicate in the space provided the specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction that can be directly attributed to this generic drug.

\_\_\_\_\_

Manufacturer / NDC \_\_\_\_\_ Dates Taken \_\_\_\_\_

Indicate in the space provided the specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction that can be directly attributed to this generic drug.

\_\_\_\_\_

Manufacturer / NDC \_\_\_\_\_ Dates Taken \_\_\_\_\_

Indicate in the space provided the specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction that can be directly attributed to this generic drug.

\_\_\_\_\_

*Note:* Pharmacy providers may provide manufacturer or NDC and dates taken.

- 
16. Explain how the BMN drug will prevent the recurrence of the unsatisfactory therapeutic response or clinically significant adverse drug reaction described in Element 15.

- 
17. Has the member taken the requested brand name drug and had a measurable therapeutic response?  Yes  No

If yes, indicate the approximate dates the brand name drug was taken.

---

**SECTION IV — AUTHORIZED SIGNATURE**

---

18. SIGNATURE — Prescriber

19. Date Signed

---

**SECTION V — ADDITIONAL INFORMATION**

---

20. Additional diagnostic and clinical information explaining the need for the drug required may be included below.
-